

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

GENAPP.002RA	(020728.0101PTUS)	PATENT
Applicant :	Gopal) Group Art Unit: 1636
Reissue Appl. :	09/404,979)
Filed :	September 22, 1999) Information Disclosure
For :	PEPTIDE-MEDIATED) Statement
	GENE TRANSFER) Under 37 C.F.R. § 1.98
Examiner: McKelvey, T.)

INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Enclosed is a listing of forty U.S. patents and one foreign patent document submitted for consideration to the Office in the above-identified application. Applicant understands that the Examiner is not to rely on this submission as an admission that these references are material to the patentability of the above-identified application. Instead, Applicant understands that the PTO will make its own full and independent review of the cited references. Applicant comments on the submitted references below.

Applicant hereby includes other patents that are related to Goers et al. by a common application, reference, or inventor for review. These additional patents are grouped together on the attached form, starting with U.S. Pat. No. 5,156,840.

Applicant hereby includes other patents that are related to Coughlin et al. by a common application, reference, or inventor for review. These additional patents are grouped together on the attached form, starting with U.S. Pat. No. 5,527,885.

Applicant hereby includes other patents that are related to Rodwell et al. by a common application, reference, or inventor for review. These additional patents are grouped together on the attached form, starting with U.S. Pat. No. 5,196,510.

Applicant hereby includes other patents that are related to Anderson et al. by a common application, reference, or inventor for review. These additional patents are grouped together on the attached form, starting with U.S. Pat. No. 5,135,736.

The Ferkol patent (U.S. Pat. No. 5,972,900) was submitted in the IDS of 3/10/04. Applicant hereby includes other patents that are related to Ferkol by a common application, reference, or inventor for review. These additional patents are grouped together on the attached form, starting with U.S. Pat. No. 6,200,801.

The Szoka patent (U.S. Pat. No. 5,955,365) was submitted in the IDS of 11/99. Applicant hereby includes other patents that are related to Szoka by a common application, reference, or inventor for review. These additional patents are grouped together on the attached form, starting with U.S. Pat. No. 6,300,317.

The Curiel patent (U.S. Pat. No. 5,547,932) was submitted in the IDS of 5/01. Applicant hereby includes other patents that are related to Curiel by a common application, reference, or inventor for review. These additional patents are grouped together on the attached form, starting with U.S. Pat. No. 6,274,322.

The Baird patent (U.S. Pat. No. 6,037,329) was submitted in the IDS of 9/00. Applicant hereby includes other patents that are related to Baird by a common application, reference, or inventor for review. These additional patents are grouped together on the attached form, starting with U.S. Pat. No. 6,551,618.

The Roop patent (U.S. Pat. No. 5,958,764) was submitted in the previous IDS. Applicant hereby includes other patents that are related to Roop by a common application, reference, or inventor for review. These additional patents are grouped together on the attached form, starting with U.S. Pat. No. 6,143,727.


The Frankel patent (U.S. Pat. No. 5,674,977) was submitted in the IDS of 12/2003. Applicant hereby includes other related patents by Frankel that cover the same invention with differing claim scope for review. These additional patents are grouped together in the attached form, starting with U.S. Pat. No. 5,804,604.

Several references found that mention a "DNA Transporter" are grouped together in the attached form, starting with U.S. Pat. No. 5,674,703.

Several patents using a common concept involving targeted ribozymes have been found and are grouped together in the attached form, starting with U.S. Pat. No. 5,599,704.

Several patents using a common concept involving the pre-targeted delivery of diagnostic and

therapeutic agents have been found and are grouped together in the attached form, starting with
U.S. Pat. No. 6,022,966.

By: 
Scott Chambers
Registration No. 37,573

Patton Boggs, LLP
8484 Westpark Drive
9th Floor
McLean, Virginia 22102
(703) 744-8085 (direct)
(703) 744-8001 (facsimile)
schambers@pattonboggs.com

SHEET 1 of 4

FORM PTO-1449

US DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.
020728.0101PTUSAPPLICATION NO.
09/404,979INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
T.Venkat Gopal

(USE SEVERAL SHEETS IF NECESSARY)

FILING DATE
September 22, 1999GROUP
1636

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	5,156,840	10-20-92	Goers et al.	540	145	3-20-89
	2	4,867,973	9-19-89	Goers et al.	424	181.1	9-13-84
	3	5,527,885	6-18-96	Coughlin et al.	534	14	6-30-94
	4	5,595,468	12-17-96	Coughlin et al.	534	14	6-27-94
	5	5,326,856	7-5-94	Coughlin et al.	534	14	4-9-92
	6	5,196,510	3-23-93	Rodwell et al.	530	324	5-7-90
	7	5,047,227	9-10-91	Rodwell et al.	424	1.49	2-4-91
	8	4,671,958	6-9-87	Rodwell et al.	424	1.53	3-9-82
	9	5,449,761	9-12-95	Belinka, Jr et al.	534	10	9-28-93
	10	4,046,722	9-6-77	Rowland	530	362	1-14-76
	11	5,135,736	8-4-92	Anderson et al.	424	1.49	8-15-88
	12	5,759,517	6-2-98	Anderson et al.	424	1.69	6-1-95
	13	6,184,356	2-6-01	Anderson et al.	530	385	4-13-98
	14	5,169,933	12-8-92	Anderson et al.	530	391.3	8-7-89
	15	5,844,089	12-1-98	Hoffman et al.	530	385	5-25-95
	16	5,844,088	12-1-98	Hoffman et al.	530	385	5-19-95
	17	5,717,058	2-10-98	Matthews et al.	530	328	2-18-94
	18	5,171,563	12-15-92	Abrams et al.	424	1.45	2-10-92
	19	5,084,441	1-28-92	Shaw et al.	514	2	8-16-88
	20	5,182,107	1-26-93	Friden	424	179.1	3-6-92
	21	4,950,599	8-21-90	Berling	435	456	1-29-87
	22	5,229,490	7-20-93	Tam et al.	530	324	12-20-90
	23	5,648,248	7-15-97	Zenke et al.	435	467	1-25-95
	24	5,670,483	9-23-97	Zhang et al.	514	14	11-30-94
	25	5,672,479	9-30-97	Johnson et al.	435	7.1	6-7-95
	26	5,893,531	12-2-97	Chiorini et al.	435	325	11-24-93
	27	5,773,227	6-30-98	Kuhn	435	7.21	6-23-93
	28	5,807,746	9-15-98	Lin et al.	435	375	6-13-94
	29	5,837,533	11-17-98	Boutin	435	320.1	9-28-94
	30	5,840,674	11-24-98	Yatvin et al.	510	392	8-1-96
	31	5,847,121	12-8-98	Yau	540	474	12-13-95
	32	5,945,100	8-31-99	Fick	424	93.21	7-31-96
	33	6,380,373	4-30-02	O'Malley et al.	536	23.5	8-21-96
	34	6,423,693	6-23-02	Schwartz, et al.	514	44	7-24-98
	35	5,641,662	8-24-97	Debs et al.	435	458	3-10-93
	36	5,071,651	12-10-91	Sabara et al.	424	186.1	3-5-90
	37	4,946,778	8-7-90	Ladner et al.	435	69.6	1-19-89
	38	4,904,582	2-27-90	Tullis et al.	435	6	6-11-87
	39	4,870,023	9-26-89	Fraser et al.	435	235.1	2-8-88

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT

SHEET 4 of 4

FORM PTO-1449

US DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.
020728.0101PTUSAPPLICATION NO.
09/404,979INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
T.Venkat Gopal

(USE SEVERAL SHEETS IF NECESSARY)

FILING DATE
September 22, 1999GROUP
1636

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	5,674,835	10-7-97	ANDROPHY ET AL.	514	2	8-6-95
	5,637,471	6-10-97	ARTAVANIS-TSAKONAS ET AL.	435	.23	8-10-97
	5,869,337	2-9-99	CRABTREE ET AL.	435	372.3	2-14-95
	5,955,647	9-21-99	FITCHEN ET AL.	800	298	11-18-96
	5,780,444	7-14-98	KAHNE	514	28	4-20-95
	5,795,870	8-18-98	KAHNE	514	26	11-7-94
	5,637,481	6-10-97	LEDBETTER ET AL.	435	69.6	9-13-93
	5,851,828	12-22-98	MARASCO ET AL.	435	328	3-30-95
	6,004,940	12-21-99	MARASCO ET AL.	514	44	12-6-94
	5,965,371	5-9-95	MARASCO ET AL.	435	7.1	5-9-95
	6,262,034	7-17-01	MATHIOWITZ ET AL.	514	44	11-25-97
	6,620,617	9-16-03	MATHIOWITZ ET AL.	435	325	4-23-01
	5,668,255	9-16-97	MURPHY	530	350	8-4-93
	5,763,209	6-9-98	SUKHATME	435	69.1	3-31-93
	5,773,583	6-30-98	SUKHATME	530	358	6-8-95
	5,563,020	12-10-98	SULLIVAN	435	458	11-19-93
	5,804,604	9-8-98	FRANKEL ET AL.	530	324	5-25-95
	5,747,641	5-5-98	FRANKEL ET AL.	530	300	5-25-95
	5,674,980	10-7-97	FRANKEL ET AL.	530	350	5-25-95
	5,670,617	8-23-97	FRANKEL ET AL.	530	300	5-25-95
	5,674,703	10-7-97	WOO ET AL.	435	69.1	12-2-93
	6,088,624	5-23-00	WOO ET AL.	514	44	2-15-98
	5,750,367	5-12-98	CHAN	435	69.1	11-8-93
	5,756,264	5-26-98	SCHWARTZ, ET AL.	424	93.2	3-9-94
	5,770,580	5-30-95	LEDLEY	514	44	5-30-95
	5,792,751	8-11-98	LEDLEY	514	44	1-21-94
	5,798,209	8-25-98	CHAN	435	6	5-26-95
	5,925,564	7-20-99	SCHWARTZ ET AL.	435	325	6-7-95
	5,958,764	9-28-99	ROOP ET AL.	435	320.1	11-1-93
	6,416,998	6-9-02	O'MALLEY ET AL.	435	325	6-7-95
	5,699,704	2-4-97	THOMPSON ET AL.	435	325	5-5-95
	5,610,052	4-11-97	THOMPSON ET AL.	435	366	8-26-92
	5,616,490	4-1-97	SULLIVAN ET AL.	435	366	1-19-93
	5,622,854	4-22-97	DRAPER	435	366	2-7-94
	5,639,655	6-17-97	THOMPSON ET AL.	435	366	4-25-94
	5,750,390	5-12-98	THOMPSON ET AL.	435	195	8-26-92
	5,801,158	9-1-98	THOMPSON ET AL.	514	44	12-23-96
	5,989,906	11-23-99	THOMPSON ET AL.	435	325	2-7-94
	6,022,966	2-8-00	GUSTAVSON ET AL.	540	474	11-22-93
	5,630,996	5-20-97	RENO ET AL.	424	1.49	8-16-93
	5,608,060	3-4-97	AXWORTHY ET AL.	540	474	2-21-95
	5,578,287	11-26-96	THEODORE ET AL.	424	1.49	11-23-93
	5,541,287	7-30-96	YAU ET AL.	530	317	7-30-98

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT